TokenPost·
Spero Therapeutics Posts $0.76 Q3 Loss Per Share, Cash Runway Into 2029
The company had $107.9 million in cash and equivalents on Sept. 30, 2026, and expects the funds to support operations into the second half of 2029.
More news
- UnchainedUnocoin Says One of Its BitGo Addresses Sent Out Transactions It Can’t Trace
- TokenPostHims & Hers Revenue Climbs 49% as Gross Margin Falls to 57%
- TokenPostArcos Dorados Approves Up to $25 Million Buyback Amid Expansion Plan
- TokenPostGrabAGun Digital Posts $21.23 Million in Q3 Revenue, Misses Estimates
- TokenPostNexxen CFO Projects 2027 Adjusted EBITDA Margin Around 34%
- TokenPostPEDEVCO Revenue Climbs 411% as Derivative Loss Drives Q3 Deficit